We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-12.88%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$430M
AUM Growth
-$69.6M
Cap. Flow
+$22.7M
Cap. Flow %
5.28%
Top 10 Hldgs %
90.74%
Holding
22
New
1
Increased
4
Reduced
8
Closed
4
Avg Time Held
3.9 quarters
Top 10 Avg Time Held
2.7 quarters
Top 20 Avg Time Held
3.9 quarters

Top Buys

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$39.3M
2
PLRX icon
Pliant Therapeutics
PLRX
+$1.34M
3
CGEM icon
Cullinan Oncology
CGEM
+$1.24M
4
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$167K
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$110K

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$15.4M
2
RPTX icon
Repare Therapeutics
RPTX
+$690K
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$611K
4
ONCR
Oncorus, Inc.
ONCR
+$553K
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$491K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RPTX icon
1
DELISTED
Repare Therapeutics
RPTX
$79.2M 18.42%
2,539,644
-21,059
-0.8% -$690K
2020 Q2
4 quarters
RXDX
2
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$70M 16.29%
2,852,009
-22,023
-0.8% -$491K
2021 Q1
1 quarter
PLRX icon
3
Pliant Therapeutics
PLRX
$61.4M
$69M 16.04%
2,367,888
+43,093
+2% +$1.34M
2020 Q2
4 quarters
CGEM icon
4
Cullinan Oncology
CGEM
$964M
$57.8M 13.44%
2,242,841
+40,434
+2% +$1.24M
2021 Q1
1 quarter
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$30.2M 7.01%
+2,585,986
New +$39.3M
2021 Q2
0 quarters
ONCR
6
DELISTED
Oncorus, Inc.
ONCR
$24M 5.57%
1,735,979
-35,807
-2% -$553K
2020 Q4
2 quarters
ORTX
7
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$17.9M 4.17%
408,197
+3,000
+0.7% +$167K
2019 Q3
7 quarters
INZY icon
8
DELISTED
Inozyme Pharma
INZY
$15.8M 3.68%
927,264
– –
2020 Q3
3 quarters
LRMR icon
9
Larimar Therapeutics
LRMR
$268M
$14.9M 3.46%
1,515,148
– –
2020 Q2
4 quarters
IMA icon
10
ImageneBio Inc
IMA
$47.8M
$11.4M 2.66%
67,896
– –
2021 Q1
1 quarter
FRLN
11
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$11.2M 2.62%
91,990
-326
-0.4% -$50.7K
2020 Q3
3 quarters
AKUS
12
DELISTED
Akouos Inc
AKUS
$10.8M 2.5%
858,027
– –
2020 Q2
4 quarters
DTIL icon
13
Precision BioSciences
DTIL
$179M
$8.16M 1.9%
21,724
-1,330
-6% -$399K
2019 Q3
7 quarters
KROS icon
14
Keros Therapeutics
KROS
$234M
$4.94M 1.15%
116,406
-284,062
-71% -$15.4M
2020 Q2
4 quarters
CRVS icon
15
Corvus Pharmaceuticals
CRVS
$846M
$1.92M 0.45%
719,132
+40,000
+6% +$110K
2019 Q3
7 quarters
GTHX icon
16
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.1M 0.26%
50,000
– –
2020 Q2
4 quarters
OVID icon
17
Ovid Therapeutics
OVID
$473M
$854K 0.2%
218,510
-29,000
-12% -$114K
2019 Q3
7 quarters
KZR icon
18
DELISTED
Kezar Life Sciences
KZR
$796K 0.19%
14,668
-2,749
-16% -$156K
2019 Q3
7 quarters
ADVM icon
19
DELISTED
Adverum Biotechnologies
ADVM
– –
-4,021
Closed -$396K –
BPMC icon
20
DELISTED
Blueprint Medicines
BPMC
– –
-3,500
Closed -$340K –
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$1.5B
– –
-2,000
Closed -$228K –
GBT
22
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-15,000
Closed -$611K –

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, CHI Advisors held 22 positions worth $430M, down 14% from $500M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

CHI Advisors deployed $22.7M of net new capital in Q2 2021, opening 1 new position and adding to 4 existing holdings. Its largest new stake was VectivBio Holding AG Ordinary Shares: 2,585,986 shares worth $30.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $15.4M trimmed.

  • CHI Advisors's largest Q2 2021 buy was VectivBio Holding AG Ordinary Shares: 2,585,986 shares worth $30.2M.
  • CHI Advisors added most to Pliant Therapeutics in Q2 2021, an estimated $1.34M increase.
  • CHI Advisors's biggest Q2 2021 reduction was Keros Therapeutics, cutting an estimated $15.4M.
  • CHI Advisors fully exited Global Blood Therapeutics, Inc. in Q2 2021, selling an estimated $611K.
  • CHI Advisors's ten largest holdings make up 91% of its $430M portfolio in Q2 2021.
  • CHI Advisors opened 1 new position and closed 4 in Q2 2021.
  • CHI Advisors's portfolio value fell 14% quarter-over-quarter to $430M.

Based on CHI Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.